

# Corporate Action Notice

March 18, 2016

## Ratio Change and Stock Distribution

**ONO Pharmaceutical Co., Ltd**

**DR CUSIP:** 682736103 / **DR ISIN:** US6827361030

**DR Ticker Symbol:** OPHLY

**Ratio:** (DSs: Underlying Share): 5:1

**BNY MELLON HAS ESTABLISHED THE  
FOLLOWING DATES FOR THIS  
CORPORATE ACTION:**

**DR Record Date:** March 31, 2016

**DR Payable Date:** April 1, 2016

**DR Distribution Rate:** 200%

**Old Ratio:** 5 DSs: 1 Ordinary Share

**New Ratio:** 3 DSs: 1 Ordinary Share

**Issuance Fee:** \$0.05

Please be advised that ONO Pharmaceutical Co., Ltd has announced a five (5) for one (1) stock split on its ordinary shares in the local market as of record date March 31, 2016. As a result, BNY Mellon will change the ratio on the ONO Pharmaceutical Co., Ltd Depositary Receipt ("DR") program. The ratio change will occur simultaneously with a 200% Depositary Share ("DS") distribution (2 additional DSs for every 1 DS held).

**Please note: A ratio change may impact the fees payable by ADR investors.**

---

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

### NEW YORK

Ravi Davis

Richard J Maehr

+ 1 212 815 2267

adrdesk@bnymellon.com

### LONDON

Jacek Jankowski

Vice President

+ 44 207 163 7427

jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at <http://www.adrbnymellon.com/files/PB43451.pdf>. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



**BNY MELLON**